Key result
Viral vector-based gene therapies hold significant promise for treating neurodegenerative diseases, but their clinical translation remains constrained by innate and adaptive immune responses.
Why the study?
Progress in gene transfer-based therapies for neurodegenerative diseases remains constrained by immune responses triggered by viral vectors through innate and adaptive pathways.
This review highlights the therapeutic potential of viral vector-based gene therapies for neurodegenerative diseases while emphasizing the need to overcome immunological barriers for successful clinical translation.
Gene therapy via viral vectors shows promise in neurodegeneration; leaves open need for larger randomized trials to establish clinical efficacy and safety.
Gene transfer-based therapies utilizing viral vectors have undergone remarkable advancements and hold significant promise in addressing neurodegenerative diseases in recent years, whose potential mechanisms include replacing or silencing pathogenic genes and delivering neurotrophic factors. Current preclinical research focuses on developing novel strategies in gene modification to combat neurodegenerative disorders. Numerous clinical trials involving viral vectors in the nervous system are either on-going or completed. Despite these advancements, progress in this field remains constrained by immune responses triggered by viral vectors, which can be triggered through innate and adaptive pathways. The present review will focus on the advances in the development and application of viral vector-based gene therapies for neurodegenerative diseases and summarize the related immune responses, aiming to provide a forward-looking perspective for this emerging arena.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a review in Neurodegenerative diseases. Viral vector-based gene therapies was evaluated. Viral vector-based gene therapies hold significant promise for treating neurodegenerative diseases, but their clinical translation remains constrained by innate and adaptive immune responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: